Syncom has a proven track record (over 27 years) in assisting leading pharma and biotechnology companies with medicinal chemistry programmes. Starting as a chemistry service provider, Syncom has transformed into an integrated drug discovery CRO offering chemistry services, in vitro screening, ADME studies, pharmacokinetics and in vivo pharmacology.
Primary chemistry activities include:
- medicinal chemistry services
- synthesis of key building blocks
- library synthesis
- route scouting service
- process research activities
- scale up and hit-to-lead optimization programmes.
On custom basis we also synthesise metabolites, impurities, reference standards and stable labelled compounds. Our services are backed by state-of-the-art analytical technologies such as HPLC, GC, LC-MS, GC-MS and NMR.
Syncom is considered to be a world leader in chiral chemistry with a strong focus on chiral resolution technology. Syncom is the inventor of the Dutch Resolution Technology and has an exceptional track record in resolving molecules through diastereomeric salt formation.
For its outstanding skills in process R&D, Syncom was elected as the winner of the Pfizer process research innovation award out of more than 100 different contract research organizations.
Syncom is located in the Groningen, the Netherlands, and employs over 100 chemists (more than 60% at PhD levels). Syncom’s track record is exemplified by successfully executing projects for 17 of the global top 20 pharma/biotech companies in 2014.
